Cargando…

(68)Ga-Radiolabeling and Pharmacological Characterization of a Kit-Based Formulation of the Gastrin-Releasing Peptide Receptor (GRP-R) Antagonist RM2 for Convenient Preparation of [(68)Ga]Ga-RM2

Background: [(68)Ga]Ga-RM2 is a potent Gastrin-Releasing Peptide-receptor (GRP-R) antagonist for imaging prostate cancer and breast cancer, currently under clinical evaluation in several specialized centers around the world. Targeted radionuclide therapy of GRP-R-expressing tumors is also being inve...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chastel, Adrien, Vimont, Delphine, Claverol, Stephane, Zerna, Marion, Bodin, Sacha, Berndt, Mathias, Chaignepain, Stéphane, Hindié, Elif, Morgat, Clément
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8398231/ https://www.ncbi.nlm.nih.gov/pubmed/34452121 http://dx.doi.org/10.3390/pharmaceutics13081160

Ejemplares similares

Comparison of the binding of the gastrin-releasing peptide receptor (GRP-R) antagonist (68)Ga-RM2 and (18)F-FDG in breast cancer samples
por: Morgat, Clément, et al.
Publicado: (2019)

Gastrin-releasing Peptide Receptor Imaging in Breast Cancer Using the Receptor Antagonist (68)Ga-RM2 And PET
por: Stoykow, Christian, et al.
Publicado: (2016)

Voxel-based comparison of [(68)Ga]Ga-RM2-PET/CT and [(68)Ga]Ga-PSMA-11-PET/CT with histopathology for diagnosis of primary prostate cancer
por: Fassbender, Thomas Franz, et al.
Publicado: (2020)

[(68)Ga]Ga-PSMA and [(68)Ga]Ga-RM2 PET/MRI vs. Histopathological Images in Prostate Cancer: A New Workflow for Spatial Co-Registration
por: Ghezzo, Samuele, et al.
Publicado: (2023)

Comparison of the radiolabeled PSMA-inhibitor (111)In-PSMA-617 and the radiolabeled GRP-R antagonist (111)In-RM2 in primary prostate cancer samples
por: Schollhammer, Romain, et al.
Publicado: (2019)

The effects of novel macrocyclic chelates on the targeting properties of the (68)Ga-labeled Gastrin releasing peptide receptor antagonist RM2
por: Wang, Yinwen, et al.
Publicado: (2023)

Gastrin-Releasing Peptide Receptor Antagonist [(68)Ga]RM2 PET/CT for Staging of Pre-Treated, Metastasized Breast Cancer
por: Michalski, Kerstin, et al.
Publicado: (2021)

(68)Ga-PSMA and (68)Ga-DOTA-RM2 PET/MRI in Recurrent Prostate Cancer: Diagnostic Performance and Association with Clinical and Histopathological Data
por: Mapelli, Paola, et al.
Publicado: (2022)

Automated Synthesis of [(68)Ga]Ga-FAPI-46 on a Scintomics GRP Synthesizer
por: Plhak, Elisabeth, et al.
Publicado: (2023)

Cyclotron-based production of (68)Ga, [(68)Ga]GaCl(3), and [(68)Ga]Ga-PSMA-11 from a liquid target
por: Rodnick, Melissa E., et al.
Publicado: (2020)

Positron Emission Tomography Imaging of Prostate Cancer with Ga-68-Labeled Gastrin-Releasing Peptide Receptor Agonist BBN(7–14) and Antagonist RM26
por: Cheng, Siyuan, et al.
Publicado: (2017)

Preliminary Results of an Ongoing Prospective Clinical Trial on the Use of (68)Ga-PSMA and (68)Ga-DOTA-RM2 PET/MRI in Staging of High-Risk Prostate Cancer Patients
por: Mapelli, Paola, et al.
Publicado: (2021)

First in-human radiation dosimetry of the gastrin-releasing peptide (GRP) receptor antagonist (68)Ga-NODAGA-MJ9
por: Gnesin, Silvano, et al.
Publicado: (2018)

Automated GMP Production and Preclinical Evaluation of [(68)Ga]Ga-TEoS-DAZA and [(68)Ga]Ga-TMoS-DAZA
por: Greiser, Julia, et al.
Publicado: (2022)

Meningiomas: A Comparative Study of (68)Ga-DOTATOC, (68)Ga-DOTANOC and (68)Ga-DOTATATE for Molecular Imaging in Mice
por: Soto-Montenegro, María Luisa, et al.
Publicado: (2014)

[(68)Ga]Ga-DOTA-TOC: The First FDA-Approved (68)Ga-Radiopharmaceutical for PET Imaging
por: Hennrich, Ute, et al.
Publicado: (2020)

Evaluation of (68)Ga-Radiolabeled Peptides for HER2 PET Imaging
por: Ducharme, Maxwell, et al.
Publicado: (2022)

[(68)Ga]Ga-RM2 PET/CT reveals small distant metastases not detected by conventional imaging in primary estrogen receptor-positive breast cancer
por: Michalski, Kerstin, et al.
Publicado: (2023)

Biodistribution of (68/67)Ga-Radiolabeled Sphingolipid Nanoemulsions by PET and SPECT Imaging
por: Díez-Villares, Sandra, et al.
Publicado: (2021)

[(68)Ga]Ga-PSMA-11: The First FDA-Approved (68)Ga-Radiopharmaceutical for PET Imaging of Prostate Cancer
por: Hennrich, Ute, et al.
Publicado: (2021)

Preparation, Characterization, and Radiolabeling of [(68)Ga]Ga-NODAGA-Pamidronic Acid: A Potential PET Bone Imaging Agent
por: Ashhar, Zarif, et al.
Publicado: (2020)

Fully automated radiolabeling of [(68)Ga]Ga-EMP100 targeting c-MET for PET-CT clinical imaging
por: Rusu, Timofei, et al.
Publicado: (2023)

Standardization of the [(68)Ga]Ga-PSMA-11 Radiolabeling Protocol in an Automatic Synthesis Module: Assessments for PET Imaging of Prostate Cancer
por: Fuscaldi, Leonardo L., et al.
Publicado: (2021)

Instant kit preparation of (68)Ga-radiopharmaceuticals via the hybrid chelator DATA: clinical translation of [(68)Ga]Ga-DATA-TOC
por: Sinnes, Jean-Philippe, et al.
Publicado: (2019)

Comparison of 99mTc radiolabeled somatostatin antagonist with [(68) Ga]Ga-DOTA-TATE in a patient with advanced neuroendocrine tumor
por: Opalinska, Marta, et al.
Publicado: (2023)

Prospective of (68)Ga-Radiopharmaceutical Development
por: Velikyan, Irina
Publicado: (2013)

A prospective head-to-head comparison of [(68)Ga]Ga-P16-093 and [(68)Ga]Ga-PSMA-11 PET/CT in patients with primary prostate cancer
por: Wang, Guochang, et al.
Publicado: (2023)

Twins in spirit - episode I: comparative preclinical evaluation of [(68)Ga]DOTATATE and [(68)Ga]HA-DOTATATE
por: Schottelius, Margret, et al.
Publicado: (2015)

Site-Specific (68)Ga Radiolabeling of Trastuzumab Fab via Methionine for ImmunoPET Imaging
por: Yue, Thomas T. C., et al.
Publicado: (2023)

Initial Clinical Experience with (68)Ga-DOTA-NOC Prepared Using (68)Ga from Nanoceria-polyacrylonitrile Composite Sorbent-based (68)Ge/(68)Ga Generator and Freeze-dried DOTA-NOC Kits
por: Chandra, Piyush, et al.
Publicado: (2017)

The (68)Ge/(68)Ga generator has high potential, but when can we use (68)Ga-labelled tracers in clinical routine?
por: Breeman, Wouter A. P., et al.
Publicado: (2007)

Artificial intelligence-based (68)Ga-DOTATOC PET denoising for optimizing (68)Ge/(68)Ga generator use throughout its lifetime
por: Quak, Elske, et al.
Publicado: (2023)

(68)Ga-Triacetylfusarinine C and (68)Ga-Ferrioxamine E for Aspergillus Infection Imaging: Uptake Specificity in Various Microorganisms
por: Petrik, Milos, et al.
Publicado: (2013)

Fully Automated Production of [(68)Ga]GaFAPI-46 with Gallium-68 from Cyclotron Using Liquid Targets
por: Fonseca, Alexandra I., et al.
Publicado: (2023)

Fully-automated production of [(68)Ga]Ga-FAPI-46 for clinical application
por: Spreckelmeyer, Sarah, et al.
Publicado: (2020)

Adventures in radiosynthesis of clinical grade [(68)Ga]Ga-DOTA-Siglec-9
por: Käkelä, Meeri, et al.
Publicado: (2018)

[(68)Ga]Ga-DOTA-TATE uptake due to COVID-19 vaccination
por: Weiler-Sagie, Michal, et al.
Publicado: (2021)

[(68) Ga]Ga-FAPI uptake correlates with the state of chronic kidney disease
por: Conen, Patrick, et al.
Publicado: (2022)

Optimization of Automated Radiosynthesis of Gallium-68-Labeled PSMA11 with Two [(68)Ge]Ge/[(68)Ga]Ga Generators: Fractional Elution or Prepurification?
por: Durieux, Flore, et al.
Publicado: (2023)

Highly variable biodistribution of (68)Ga labeled somatostatin analogues (68)Ga-DOTA-NOC and (68)Ga-DOTA-TATE in neuroendocrine tumors: clinical implications for somatostatin receptor directed PET/CT
por: Cheng, Monica, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_fs029cn1nf6h48cvnd6c4a3b7k